Related Experiment Videos

Gluconate calcium therapy and neonatal hypercalciuria

Insights

Premature infants receiving furosemide or intravenous calcium gluconate may develop hypercalciuria, increasing nephrolithiasis risk. This study highlights the impact of these therapies on infant kidney health.

Area of Science:

  • Pediatric Nephrology
  • Neonatal Intensive Care

Background:

  • Premature infants with bronchopulmonary dysplasia often receive furosemide and intravenous calcium gluconate.
  • Hypercalciuria and nephrolithiasis have been observed in infants on these therapies.

Observation:

  • This study investigated sick infants receiving calcium gluconate without furosemide.
  • Urinary calcium excretion was compared between sick infants on calcium gluconate and well infants on regular formula.

Findings:

  • Sick infants receiving calcium gluconate exhibited higher urinary calcium levels than healthy infants.
  • Calciuria appeared to increase progressively with continued calcium gluconate therapy.

Implications:

  • Prolonged use of furosemide or intravenous calcium gluconate can lead to hypercalciuria in premature infants.
  • Hypercalciuria may predispose premature infants to developing nephrolithiasis (kidney stones).

Related Concept Videos